227 related articles for article (PubMed ID: 31136417)
21. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
22. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
26. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.
Cojutti PG; Lugano M; Righi E; Della Rocca G; Bassetti M; Hope W; Pea F
Eur J Clin Pharmacol; 2018 Nov; 74(11):1449-1459. PubMed ID: 30032414
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Liu P; Mould DR
Antimicrob Agents Chemother; 2014 Aug; 58(8):4718-26. PubMed ID: 24913161
[TBL] [Abstract][Full Text] [Related]
29. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
[TBL] [Abstract][Full Text] [Related]
31. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.
Pavie J; Lacroix C; Hermoso DG; Robin M; Ferry C; Bergeron A; Feuilhade M; Dromer F; Gluckman E; Molina JM; Ribaud P
J Clin Microbiol; 2005 Sep; 43(9):4902-4. PubMed ID: 16145172
[TBL] [Abstract][Full Text] [Related]
32. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
[TBL] [Abstract][Full Text] [Related]
34. Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey.
He SY; Makhzoumi ZH; Singer JP; Chin-Hong PV; Arron ST
Transpl Infect Dis; 2015 Feb; 17(1):14-20. PubMed ID: 25620387
[TBL] [Abstract][Full Text] [Related]
35. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
36. Disposition of posaconazole after single oral administration in large falcons (Falco spp): Effect of meal and dosage and a non-compartmental model to predict effective dosage.
Azmanis P; Pappalardo L; Sara ZAJ; Silvanose C; Naidoo V
Med Mycol; 2021 Sep; 59(9):901-908. PubMed ID: 33891699
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of voriconazole in adults.
Hope WW
Antimicrob Agents Chemother; 2012 Jan; 56(1):526-31. PubMed ID: 22064545
[TBL] [Abstract][Full Text] [Related]
38. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
Martin JM; Macias-Parra M; Mudry P; Conte U; Yan JL; Liu P; Capparella MR; Aram JA
Pediatr Infect Dis J; 2017 Jan; 36(1):e1-e13. PubMed ID: 27636722
[TBL] [Abstract][Full Text] [Related]
39. Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation.
Ustun C; DeRemer DL; Steele JC; Forseen C; Fisher JF; Jillella AP
Int J Antimicrob Agents; 2008 Oct; 32(4):365-6. PubMed ID: 18572390
[No Abstract] [Full Text] [Related]
40. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Liu P; Mould DR
Antimicrob Agents Chemother; 2014 Aug; 58(8):4727-36. PubMed ID: 24914120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
